22408439|t|Neuroprotective effects of pre-treatment with l-carnitine and acetyl-L-carnitine on ischemic injury in vivo and in vitro.
22408439|a|The therapeutic effect of stroke is hampered by the lack of neuroprotective drugs against ischemic insults beyond the acute phase. Carnitine plays important roles in mitochondrial metabolism and in modulating the ratio of coenzyme A (CoA)/acyl-CoA. Here, we investigate the neuroprotective effects of l-carnitine (LC) and Acetyl-l-carnitine (ALC) pre-treatment on ischemic insults under the same experimental conditions. We used a transient middle cerebral artery occlusion (MCAO) model to evaluate the protective roles of LC and ALC in acute focal cerebral ischemia in vivo and to understand the possible mechanisms using model of PC12 cell cultures in vitro. Results showed that ALC, but not LC, decreased infarction size in SD rats after MCAO in vivo. However, both LC and ALC pretreatment reduced oxygen-glucose deprivation (OGD)-induced cell injury and decreased OGD-induced cell apoptosis and death in vitro; at the same time, both of them increased the activities of super oxide dismutase (SOD) and ATPase, and decreased the concentration of malondialdehyde (MDA) in vitro. Thus, our findings suggested that LC and ALC pre-treatment are highly effective in the prevention of neuronal cell against ischemic injury in vitro, however, only ALC has the protective effect on neuronal cell injury after ischemia in vivo.
22408439	46	57	l-carnitine	Chemical	MESH:D002331
22408439	62	80	acetyl-L-carnitine	Chemical	MESH:D000108
22408439	84	99	ischemic injury	Disease	MESH:D017202
22408439	148	154	stroke	Disease	MESH:D020521
22408439	212	220	ischemic	Disease	MESH:D002545
22408439	253	262	Carnitine	Chemical	MESH:D002331
22408439	344	360	coenzyme A (CoA)	Chemical	MESH:D003065
22408439	361	370	acyl-CoA.	Chemical	MESH:D000214
22408439	423	434	l-carnitine	Chemical	MESH:D002331
22408439	436	438	LC	Chemical	MESH:D002331
22408439	444	462	Acetyl-l-carnitine	Chemical	MESH:D000108
22408439	464	467	ALC	Chemical	MESH:D000108
22408439	486	494	ischemic	Disease	MESH:D002545
22408439	563	595	middle cerebral artery occlusion	Disease	MESH:D020244
22408439	597	601	MCAO	Disease	MESH:D020244
22408439	645	647	LC	Chemical	MESH:D002331
22408439	652	655	ALC	Chemical	MESH:D000108
22408439	671	688	cerebral ischemia	Disease	MESH:D002545
22408439	754	758	PC12	CellLine	CVCL:0481
22408439	803	806	ALC	Chemical	MESH:D000108
22408439	816	818	LC	Chemical	MESH:D002331
22408439	830	840	infarction	Disease	MESH:D007238
22408439	852	856	rats	Species	10116
22408439	863	867	MCAO	Disease	MESH:D020244
22408439	891	893	LC	Chemical	MESH:D002331
22408439	898	901	ALC	Chemical	MESH:D000108
22408439	923	937	oxygen-glucose	Chemical	-
22408439	1171	1186	malondialdehyde	Chemical	MESH:D008315
22408439	1188	1191	MDA	Chemical	MESH:D008315
22408439	1237	1239	LC	Chemical	MESH:D002331
22408439	1244	1247	ALC	Chemical	MESH:D000108
22408439	1304	1317	neuronal cell	Disease	MESH:D002292
22408439	1326	1341	ischemic injury	Disease	MESH:D017202
22408439	1366	1369	ALC	Chemical	MESH:D000108
22408439	1399	1412	neuronal cell	Disease	MESH:D002292
22408439	1426	1434	ischemia	Disease	MESH:D007511
22408439	Negative_Correlation	MESH:D000108	MESH:D002292
22408439	Negative_Correlation	MESH:D002331	MESH:D017202
22408439	Negative_Correlation	MESH:D000108	MESH:D020244
22408439	Negative_Correlation	MESH:D000108	MESH:D007511
22408439	Association	MESH:D002331	MESH:D003065
22408439	Comparison	MESH:D000108	MESH:D002331
22408439	Negative_Correlation	MESH:D002331	MESH:D002545
22408439	Negative_Correlation	MESH:D000108	MESH:D008315
22408439	Negative_Correlation	MESH:D000108	MESH:D007238
22408439	Negative_Correlation	MESH:D002331	MESH:D008315
22408439	Negative_Correlation	MESH:D002331	MESH:D002292
22408439	Negative_Correlation	MESH:D000108	MESH:D017202
22408439	Negative_Correlation	MESH:D000108	MESH:D002545

